GH Research PLC (NASDAQ:GHRS) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Shares of GH Research PLC (NASDAQ:GHRS) have earned a consensus rating of “Moderate Buy” from the twelve analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $45.00.

Several research analysts have weighed in on the company. Zacks Research raised GH Research from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a report on Thursday, October 15th. New Street Research set a $65.00 price target on GH Research in a research note on Monday, August 10th. Wall Street Zen cut GH Research from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, HC Wainwright restated a “buy” rating on shares of GH Research in a report on Monday, August 10th.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Troluce Capital Advisors LLC increased its stake in shares of GH Research by 165.4% during the 1st quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock worth $13,926,000 after purchasing an additional 617,260 shares during the last quarter. Braidwell LP acquired a new stake in shares of GH Research in the 2nd quarter valued at $5,571,000. Renaissance Technologies LLC acquired a new stake in shares of GH Research in the 1st quarter valued at $290,000. Squarepoint Ops LLC acquired a new position in GH Research during the second quarter worth $495,000. Finally, Farther Finance Advisors LLC increased its position in GH Research by 9,720.0% during the third quarter. Farther Finance Advisors LLC now owns 9,820 shares of the company’s stock worth $231,000 after buying an additional 9,720 shares during the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Trading Up 4.4%

Shares of NASDAQ:GHRS opened at $20.02 on Wednesday. GH Research has a 1 year low of $12.04 and a 1 year high of $31.44. The business has a fifty day simple moving average of $24.56 and a 200 day simple moving average of $21.41. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of -20.02 and a beta of 1.32.

GH Research (NASDAQ:GHRS) last issued its earnings results on Thursday, August 6th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.06. On average, sell-side analysts forecast that GH Research will post -1.20 EPS for the current year.

About GH Research

GH Research plc is a clinical-stage biopharmaceutical company focused on developing novel therapies for psychiatric and neurological disorders. The company is headquartered in Dublin, Ireland, and conducts research and clinical development activities through its proprietary pipeline of psychedelic-based medicines.

Its lead program, GH001, is an investigational inhaled formulation of mebufotenin, also known as 5-MeO-DMT. GH Research has studied GH001 in patients with treatment-resistant depression, with the aim of developing a rapidly acting treatment that may provide meaningful improvements following a short course of administration.